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I. INTRODUCTION
The United States has gone back and forth over whether its citizens have a
moral right to access potentially life sustaining or lifesaving treatment when they
are terminally ill.' Currently, forty-one states and the US Senate have passed
"right to try" laws that permit terminally ill patients to have access to
experimental treatments that have not yet received FDA approval.2 The United
States has had a difficult time determining whether a patient has the right to
refuse life-sustaining or lifesaving treatment because of fear that the patient is
*J.D. Candidate 2019, University of Georgia School of Law
1 See, e.g., Pavlos Eleftheriadis, A Right to Health Care, J.L. MFD. & ETHICS, 268 (2012)
(describing the dichotomy between the moral theories of right to try versus right to die).
2 RIGHTToTRY.ORG, http://righttotry.org/rtt-faq/ (Last visited Nov. 18, 2018). S. Res.
204, 115th Cong. (2017) (enacted).
1
Laney: The Shifting Landscape of Medicine: Patents of Personalized Biolo
Published by Digital Commons @ Georgia Law,
J. INTELI PROP. L
suicidal.3 The Supreme Court has addressed this problem and determined that
the State does have an interest in preserving the healthy lives of its citizens.
4
This dilemma is complicated further by the prospect of personalized
medicine, i.e. the use of medicine specifically created for one particular
individual. With this narrow application, there would likely be no commercial
viability for the treatments elsewhere. Further, due to the complicated nature of
these medications, the Supreme Court has allowed "biosimilar" patents, which
allow non-exact copies of a drug to be made.5 This is unlike, and potentially less
rigorous than, the standard FDA approval requirements.
6
This Note addresses the problems that arise when the patent protectors of
the personalized product interfere with the patient's right to receive treatment
and the state's interest in protecting its citizens by making medical treatment
available. If the patient cannot afford the personalized medication, and it is the
only treatment, is there a right to the treatment? If the patient consented to the
creation of the personalized and lifesaving treatment (not just experimental), is
there a right to refuse the treatment at a later date?
First, this Note will explain what personalized medicine is, and give an
overview of how treatment can be so precisely designed for each individual's
genomic makeup. Second, this Note will examine the property rights of one's
genetic information, especially when that information is obtained without the
patient's consent. Third, this note will summarize the process for patenting these
biologic products a. Fourth, this Note will provide a description of the Abigail
Alliance case and the idea of medical self-defense. Finaly, this Note will argue
why patents of this nature will interfere with the idea of the moral "right to try"
and how that interference will require incentive structuring for medical
innovation to change.
3 Claire Andre & Manuel Velasquez, Assisted Suicide: A Right or Wrong?, Markkula Center
for Applied Ethics ov.2l15https://www.scu.edu/ethics/focus-areas-bioethics/resources/
assisted-suicide-a-right-or-a-wrong/.
4 Cruzan ex rel Cruzan v. Dir., Mo. Dep't of Health, 497 U.S. 261, 280 (1990).
5 Patient Protection and Affordable Care Act; Title VII - Improving Access to Innovative
Medical Therapies, 42 U.S.C. §262(e) (2011).
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II. BACKGROUND
A. PERSONALIZED MEDICINE
Personalized medicine is the "tailoring of medical treatment to the individual
characteristics of each patient."7 This new approach to healthcare will analyze
the patient's genetic code, life style, and other environmental factors to provide
specifically tailored treatments and therapies.8 In general, patients will be
identified by particular "biomarkers.9" These biomarkers will let medical
providers know what type of drug and what dose would be most effective, while
producing the least amount of side effects.10 This level of precision will allow
patients with certain cancers to be offered a "molecular diagnosis," which allows
their physician to select specific treatments that will respond best to the disease
and the patient.1 For instance, a cancer, such as melanoma can be broken down
into subcategories of conditions that will give the physicians a better idea of the
behavior of the cancer and how best to treat it.12
The landscape of this healthcare model is changing dramatically due to the
innovations in the genetic mapping of humans, specifically the genotyping of
drug-metabolizing enzymes.13 Today, the cost and labor to map one's genome
is a fraction of what it was just ten years ago.14 Because of this reduction in cost,
there have been thousands of human genomes sequenced.'5 This mapping has
allowed researchers to create over one hundred ifferent genomic medications.16
Furthermore, there have been new advancements in medical research that
will allow providers to test treatments and medications on the individual without
risking harm to that individual.17 Researchers at the Wyss Institute have created
7 U.S. FOOD & DRUG ADMIN., Paving the Wyajfor Persona/ized Medicine: FDA's Role in a New
Era of Medical Product Development 7 (2013) (last visited Aug. 25, 2018) (quoting the President's
Council of Advisors on Science and Technology), http://www.fdanews.com/ext/resources/
files/10/10-28 -13-Personalized-Medicine.pdf.
8 See id.
See generally, Personalizred Medicine: Identifying the Appropriate Patient Through Biomarkers in
Oncology, PHARMACY AND THERAPEUTCS, Vol 36 (Jul. 2011), https://www.ncbi.nlm.nih.gov/
pmc/articles/PMC3171807/.
10 See Personalized Medicine Coalition, The CaseforPersonaiZedMedicine, 4 (4th ed. last visited
Aug. 25, 2018), http://www.personalizedmedicinecoaltion.org/userfiles/PMC-Corporate/







17 Laura Levis, Mimicking Organs, HARV. MAG., Jan. 12 - Feb. 14, 2016.
2019]
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"human-organs-on-chips" that are able to mimic an individual's physiologyi
These microchips "recapitulate the microarchitecture and functions of living
human organs, including the lung, intestine, kidney, skin, bone marrow and
blood brain barrier."' 9 These chips can mimic the microenvironment of the
organs, which allows researchers to test different treatments directly on one's
organs as well as enable researchers to test how environmental factors may affect
tissue, such as smoking's effect on one's lungs.
20
This work will drastically increase the number of biomarkers identified as well
as increase the specificity to which these treatments will be tailored to a particular
individual.21 With more biomarkers identified, pharmaceutical companies will be
able to more easily produce these "pharmacogenomic drugs," or drugs that use
the specific map of the patient's genes to design and control specific aspects of
the medication.22 With a line of more particularized pharmaceuticals, these
manufacturers will have a strong interest in maintaining control of these drugs
through the use of patents.
B. PATIENT'S RIGHTS TO GENETIC INFORMATION:
To understand the tight of patients to own their genetic material, one must
first understand the reach and purpose of patent law. Patents allow creators to
have individual monopolies over certain items or methods, which excludes
others from making, using, or selling the patented subject.2
3 The idea is that
allowing inventors and designers to have control over their product will
encourage others to create and develop new technologies that will benefit
humanity.24 The government protects this right and states that "whoever invents
or discovers any new and useful process, machine, manufacture, or composition
of matter, or any new and useful improvement thereof, may obtain a patent
therefore.'25 One limit to that definition is that objects that naturally occur in






22 Drug-Gene Testing (Pharmacogenomics), MAYO CNIc, http://mayoresearch.mayo.edu/
center- for-individualized-medicine/drug-gene-tesring.asp (last visited Oct. 16, 2018).
23 Herman v. Youngstown Car Mfg. Co., 191 F. 579-84 (6th Cir. 1911).
24 See generaly, David S. Olson, Taking the Utiliarian Basis for Patent Law Seriousy: The Case for
Restricting Patentable Subject Matter, 82 TEMP. L. REV. 181 (2009).
- 35 U.S.C. 5101 (1952).
26 Leland L. Black, Patenting and Protecting Personalized Medicine Innovation Post-Mayo,
Myriad, and Limelight, 95 N.C. L. REV. 493, 503 (2017).
[Vol. 26:1
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Although one's genetic information is considered to be naturally occurring,
the Supreme Court held in Assn. for Molecular Pathology v. Myriad Genetics, Inc.,27
that the stable, lab-generated complementary DNA (cDNA) of the same gene is
patentable.28 In Myriad, medical organizations brought an action against the
Patent and Trademark Office (PTO) challenging the validity of patents for DNA
sequences associated with a predisposition to breast and ovarian cancers and
methods for identifying particular mutations in those sequences.29 The Court
held that "cDNA differs from DNA in that the non-coding regions have been
removed.'30 The cDNA's sequence may be dictated by nature, but without the
coding regions, the cDNA would not be able to replicate or exist in nature.31 The
Court reasoned that a lab technician creates something new when cDNA is
made,32 even though cDNA is nothing more than a mirror image of the organic
gene.
33
The decision in Myriad opens the door for almost any DNA sequence to be
patented so long as it is isolated, copied, and the original gene has its own
introns.34 Introns are portions of a DNA sequence that do not code genetic
information.35 The importance of the lack of introns regarding patentability is
that, if the gene did not have its own introns, then there would be no difference
between the organic gene DNA and the cDNA.36 And, if the sequence of the
cDNA is indistinguishable from that of the organic DNA sequence, then the
cDNA sequence cannot be patented.37 So long as the targeted DNA sequence
has its own introns, the cDNA sequence can be patented, which would include
a significant number of gene sequences for each individual.38
One of the growing concerns about personalized medicine and the use of
genetic information for medical research is that the individual no longer has
complete control over his or her "body." This is not a new issue and has actually
found its way into the courts before.39 In Moore v. Regents of Univ. of Cal., John
Moore was receiving medical treatment for hairy-cell leukemia at the Medical
27 569 U.S. 576 (2013).
28 See Id.
29 Id
30 Id. at 581.
31 Id.
32 Olson, supra note 25.
33 See Megan Krench, New Supreme Ct. Decision Rules That cDNA is Patentable: What It Means
for Research and Genetic Testing, SCIENTIFIC AMERICAN (Jul. 9, 2013), https://
blogs.scientificamerican.com/guest-blog/new-supreme-court-decision-rules-that-cdna-is-
patentablewhat-it-means- for-research-and-genetic-testing/.
34 Dan Liu, Owning The Code, 36-DEC L.A.L. 20, 25 (2013).
35 Id. at 24.
36 Id. at 25.
37 Id.
38 See supra note 34.
39 249 Cal. Rptr. 494, 498 (Ct. of App. 1988), superseded by 271 Ca. Rptr. 146 (1990).
2019]
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Center of the University of California.4° As a part of his treatment, his physician,
Dr. David Golde, removed Moore's spleen.
41 It turned out that the patient's cells
were unique and the cell line could produce "pharmaceutical products with
enormous therapeutic and commercial value."
'42 Without telling the patient, Dr.
Golde patented the cell-line and teamed up with a pharmaceutical company that
estimated the potential market of these products to be three billion dollars.
43
Moore filed a lawsuit against Dr. Golde and the research facility for conversion
and lack of consent.44 Moore further alleged that his "spleen, blood, and the cell-
line derived from his cells 'are his tangible personal property.' ',45 The California
Supreme Court, however, held that Moore did not have a cause of action for
conversion because he "clearly did not expect to retain possession of his cells
following their removal."'46
This ruling is significant, but limited to the state of California. It is also
significant that, following the ruling, research and treatment facilities have been
better about clarifying intentions and obtaining proper consent from their
patients.47 Thus, because the court in Moore relied heavily on the intentions of
the parties it did not fully answer the question of what happens when the entire
purpose of creating the treatment is to provide treatment for that individual. Nor
does the result guide decisions regarding genetic information being obtained
without consent. As a result, the tissues of millions of Americans are used in
medical research without their knowledge or consent, leaving the issue of
patentability unresolved and relevant.
48
C. PATENTING BIOLOGICS AND PHARMACOGENOMICS:
Biologics are any pharmaceutical drug synthesized from a biological source,
such as a protein, virus, blood component, or other living cell.
49 A biosimilar
product is one that is "highly similar" to, and has no clinically meaningful





45 Id at 503.
46 Moore v. Regents of Univ. of Cal., 51 Cal. 3d 120, at 154 (1990).
47 See generaly, Robert Klitzman, How IRBs View and Make Decisions About Consent Forms, 8 J.
EMpIIucAL RES. ON Hum. REs. ETHICS 8 (2013).
48 Rebecca Skloot, Your Ce/Is. Their Research. Your Permission?, N.Y. TMES, Dec. 30, 2015,
https://www.nytimes.com/2015/12/30/opinion/your-cells-their-research-your-
permission.honl.
49 WhatAre '73iologics"Questions andAnswers, FDA Basics, https://www.fda.gov/aboutfda/
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difference from, an existing FDA-approved reference product.50 Biosimilars are
allowed because biologics are much more complicated than normal drugs and
are very sensitive to the manufacturing process.51 After the patent expires,
follow-on manufacturers will not have access to the exact ingredients,
environment, and processes that the originator used, and therefore, the follow-
on manufacturers would not be able to meet the strict standards the FDA has
set forth for other generic drugs.
52
Because no competing manufacturer could create an exact copy of the
original drug, the FDA has published broader standards for biologics to be
classified as a biosimilar or "follow-on biologic," which requires that the new
biologic satisfy all five criteria set forth in the PHSA 535(E)(k).5 3 First, the
biologic must be substantially significant to the reference product.5 4 Second, the
biologic must use the same mechanisms of action.55 Third, the reference product
must be licensed for the use prescribed, recommended, or suggested.5 6 Fourth,
the biologic and reference product must have the same route of administration,
dosage form, and strength.57 Finally, the facility where the biosimilar product is
manufactured must meet standards sufficient to assure the product is safe.5 8
These standards uphold the principles of FDA approval for generic
pharmaceuticals in that the drugs must be safe and have the same effects as the
original, but the FDA has relaxed its requirement of exact duplication.59 The
FDA clarifies that to be "highly similar," the drug must be similar in structure
and function, including the chemical identity.60 The differences that the FDA
allows for these biosimilar products are merely the inactive components of the
product.61 Examples of these inactive components include the particular
stabilizer or buffer the drug may use.
62
The difference-and-precision standard that a biologic follow-on must meet
becomes important as the prevalence of pharmacogenomics increases.
Pharmacogenomics is the study of how the genome of an individual affects his
50 Biosimilar and Interchangeable Products, FDA, https://www.fda.gov/Drugs/
DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplicatio
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or her response to drugs.63 Pharmacogenomics can look at particular marker
genes as well as how the entire genome functions and interacts with the drug.
64
Further, with the extreme improvements in technology and the large number of
genomes that have been sequenced, the field of pharmacogenomics has
increased dramatically.65 Two big changes are responsible for this revolution:
the first is testing and human research, and the second is new understandings of
certain diseases and the different approaches to treat them.
66
First, regarding human research, with the breakthrough of "gut-on-a-chip"
technology, the individual does not have to be the direct subject of the test.
67
Further, the patient does not even have to be present in the laboratory or even
the same state.68 As stated earlier, the lab will have a micro-simulation of the
patient's organs and will be able to run various tests that will show how the
individual's organs react to particular drugs.69 This would in effect allow the
medical providers to tell beforehand whether the standard version of the drug
will produce severe adverse effects or react poorly with other medications that
the individual is taking before the patient actually receives the treatment.
70
The second breakthrough is the molecular-targeted therapy in oncology.
71
This therapy looks at molecular alterations that may serve as predictors in one's
genome, which "can be simple DNA sequence variants or complex
chromosomal rearrangements.72 Doctors will be able to look at an individual's
genome and determine, based on the markers that exist or altered, that the
individual will be predisposed to certain types of cancers.73 The best example of
this is the BRCA1 and BRCA2 genes that were identified in the Myriad case.
74
Further, this new technology is not limited to cancers and can be used in a wide
variety of treatments, from hormonal therapies to understanding how a patient
will interact with anesthesia.
75
63 Roberta Ferraldeschi and William Newman, Pharmacogeneics and Pharmacogenomics: A












75 See generaly id. (describing the effects of molecular targeting on hormone therapies); and
Gordon Bush, Pharmacogenomics and Anesthesia, 61 PROC. Soc. R. MED.(1968) (identifying the
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D. MEDICAL SELF-DEFENSE
Self-defense is a long recognized and widely accepted right.7 6 It is accepted
to the point that almost no courts have put restrictions on self-defense, and other
courts have directly considered whether it is a constitutional right.77 In a plurality
opinion in Montana v. Egelhoff, Justice Scalia suggested that the right to self-
defense is protected by the Constitution.78 Self-defense is so broad, that the
Supreme Court has recognized the right of self-defense in the medical field.79 In
Roe and Casey, the Supreme Court recognized that a woman has the right to an
abortion when it is necessary "to preserve the life or health of the mother. 80
This reasoning can also be described as "a right to defend oneself using medical
care."81 Although this right has not been applied in any other medical setting, it
seems logical that the right must extend beyond just post-viability abortions.82 It
seems obvious that in certain circumstances, if there is a medical treatment that
would be necessary to save someone's life, the doctrine of self-defense should
apply.
One example of the prevalence of the idea of medical self-defense is that
bishops and other Catholic leaders are supporting doctors in Catholic hospitals
to perform abortions if it is medically necessary to save the life of the mother.83
It is a rare and unique circumstance but, nonetheless, real.8 4 In fact, the ACLU
filed a suit against Trinity Health Corporation due to a systematic failure to
provide women with appropriate emergency abortions as required by federal
law.85 Trinity Health Corporation ("Trinity") is a Catholic health system, which
owns and operates more than 80 hospitals in the United States.86 Further, Trinity
requires that all of its hospitals abide by the Ethical and Religious Directives for
Catholic Health Care Services.87 One of these directives includes the prohibition
of Catholic hospitals from performing emergency abortions if there is a
pregnancy complication, even though the abortion may be the only way to save
76 Eugene Volokh, MedcalSelf-Defense, Prohibited Experimental Therapies, and Paymentfor Organs,
120 HARV. L. Ri;v. 1813, 1818 (2007).
77 Id.
78 Id.
79 Id. at 1824
80 Id. (citing Roe v. Wade, 410 U.S. 113, 163-64 (1973) and Planned Parenthood ofSe. Pa.
v. Casey, 505 U.S. 833 (1992)).
81 Id.
82 Id.
83 See generally, Matthew Newsome, Aborion andDouble Efet, CATHOLIC ANSWERS (Sept. 1,
2006) (https://www.catholic.com/magazine/print-edition-abortion-and-double-effect).
84 Id.
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the woman's life.88 The ACLU brought this claim under EMTALA, the
Emergency Medical Treatment and Active Labor Act.89 However, the court
dismissed this case due to lack of standing, and no conclusions were reached as
to whether the right existed under the Act.90
Although the ACLU's complaint failed, the argument of medical self-defense
was also raised in Abigail Alliance v. Eschenbach.91 There, the court held that
terminally ill patients did not have a fundamental right of access to medical
treatment under the common law doctrine of self-defense.92 The Abigail Alliance
for Better Access to Developmental Drugs (the "Alliance') was an organization
that wanted to expand access to experimental medications that had not been
FDA certified for terminally ill patients.93 However, the court found that the Due
Process Clause of the Fifth Amendment, which provides that no person shall be
deprived of "life, liberty, or property, without due process of law,"94 did not
protect a terminally ill adult's access to investigational drugs.95 Further, the
common law doctrine of necessity was not enough to recognize it as a
fundamental right.96 The common law doctrine of self-defense does not weigh
in favor of recognizing access to treatment as a fundamental right because the
patients were not using "reasonable force" to defend themselves when they took
unproven and possibly unsafe drugs.97 However, all of this reasoning changes




Even with Moore and AbigailAlliance on the books, other states are taking a
different approach to the issue of property tights over genetic information and
the tight to access. Thirty-seven states have adopted "tight to try" laws stating
that a terminally ill patient does have the right to access experimental drugs that
have not received FDA approval if there is a chance that the medication could
88 Id. at 3.
89 Id. at 1.
90 ACLU v. Trinity Health Corporation, No. 15-cv-12611 (E.D. Mich. Apr. 11, 2016).
91 495 F. 3d 695 (D.C. Cir. 2007).
92 Id. at 710.
93 Id. at 697.
94 U.S. CONST. amend. V.
95 Volokh, supra note 76, at 1827.
96 Abigail Alliance, 495 F.3d at 696.
97 Id. at 723.
98 S. Res. 204, 115th Cong. (2017) (enacted).
[Vol. 26:1
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save their lives.99 The overwhelming support for passing these laws shows that
our country has a moral interest in providing people with the best possible
options to survive.1°° Further, one of the basic principles of law is that it is the
responsibility of the legal institution to reflect the moral inclinations of society,
which in this case means the law should not limit the rights of terminal patients
to use untested, experimental drugs.
Despite state legislatures' best intentions, the way in which the
pharmacogenomic drugs are patented will have an effect on whether a patient
would have access to potentially lifesaving treatment, even with the right-to-try
laws. On one hand, if the patent of the patient's particular medicine is novel,
then the medication will be subject to the standard FDA approval process but
may also fit within the exceptions of the tight-to-try laws. Alternatively, if the
new medication is similar enough in nature to other biologics, then it will not
need to be put through the same laborious process of FDA approval.101 Avoiding
the standard FDA process may also eliminate the new medication's eligibility for
general access under the right-to-try laws, even though the typical ethical issues
surrounding the right-to-try laws would not apply, such as, "using humans as
guinea pigs" and "the giving of false hope." Additionally, if the treatment is
certified to be similar, then that would be even more evidence of the drug's
effectiveness. This will give the patient a stronger argument that the new
pharmacogenomic drug will actually be lifesaving, and under medical self-
defense, the patient should have a right to access the treatment.
The right to access life-sustaining or lifesaving treatments further depends on
the method by which the biotech or pharmaceutical company obtained the
patient's genetic information. If the patient contracted with the company to
develop a specialized treatment for their disease, they would likely have waived
certain claims of necessity in their consent form.102 However, as stated earlier,
there are millions of Americans that have their tissue samples being
experimented on without their knowledge and/or consent.10 3 Further, contained
in everyone's tissues are their DNA and gene sequences, which means that these
labs have access to millions of people's genes, but the people have not consented
to research or waived any particular rights.104
Additionally, with the organizations like "23andME," "deCODEME," and
"Knome," the number of people who have unwittingly given their genetic
99 Goldwater, U.S. Senate Approves Right to Ty Law, RIGHTrOTRY.ORG (Aug. 4, 2017),
http://righttotry.org/u-s-senate-approves-right-to-try-law/.
100 Id.
101 Biosimilar and Interchangeable Products, supra note 50.
102 See generally Amy McGuire & Laura Beskow, Informed Consent in Genomics and Genetic
Research, 11 ANN. REv. GENOMJCs HUM. GENETICS 361-68 (2010).
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information away to corporations is even higher.1
0 5 23andMe does not make a
large profit from its $100 genetic test kits; instead, it makes its profits from the
genetic information that it sells to third parties.06 Although the companies claim
they de-identify the data before they sell it, they still keep the genetic profiles of
their participants on their private records.0 7 Additionally, there are currently no
regulations preventing them from divulging that personal and identified
information to third party companies that have the intention of developing new
pharmacogenomics.108
Because the field of these genetic tests and genomic profiles lack proper
oversight, and the public is substantially uneducated on these topics, it is
necessary to have substantive laws in place that will protect individuals from
pharmaceutical companies effectively having monopoly over potentially
lifesaving treatment.
In one notable example, a man interested in knowing whether his family was
more Irish or Welsh purchased a home genetic kit from 23andMe. As it turns
out, the test told him not only that he was over 60% Irish, but also that he had
genetic markers indicating predisposal to heart disease, just like his father and
grandfather. What the information pack he did not tell him was that the company
would continue to use his genetic information for further testing. This testing
showed that there was a different, less common combination of markers that
identified a strong likelihood of developing kidney disease. Instead of informing
all of the people with these markers, the company sold that information to a
third-party pharmaceutical company that was developing new kidney
medications. During the development of these new medications, the
pharmaceutical company discovered that those uncommon genetic markers also
had an extremely adverse effect to the more common treatments for heart
disease. Armed with this discovery, the pharmaceutical company developed a
new type of treatment for this rare form of kidney disease.
After a few years, the man developed kidney disease and went to his doctor.
The pharmaceutical company reached out to his doctor, notifying him of the
patient's unique form of the disease, and claimed to have the only appropriate
treatment. The company informed the physician that the standard treatment
would be ineffective and may even have adverse effects on the patient. If the





108 Jane Kaye, The Regulation of Direct-to-Consumer Genetic Tests, 17 HUM. MOLECULAR
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patient did not receive this particularized treatment, he would most likely die
within six months.
The doctor, wanting to adhere to best practices and do good for the patient,
prescribed the unique treatment. However, the cost was 400 times the price of
the standard treatment. Unsurprisingly, the man could not afford it. So, the
question becomes, does he get to be treated anyways? And if so, through what
channel should he be provided this treatment? Should he have a right to the
treatment if he cannot afford it?
The argument for his right to the treatment is that it was discovered and based
on his own genetic information, and it is likely the only treatment that will save
him from a terminal condition. A man in this position would be able to claim a
property interest in the genetic information that was derived from his tissue
sample. Further, the particular sample that was used for the research was arguably
obtained without his consent for that specific use, and therefore he did not waive
any rights he had in that genetic information.
Does the patient deserve the treatment out of the doctrine of medical
necessity? The argument here is that he is terminal without the particularized
treatment, and his only mode of survival is to be given this one particular
treatment. If drastic measures are used in other circumstances, why not use less
these, relatively less drastic, measures to save the patient here? If we require
physicians to terminate a pregnancy to save the life of a mother, which is
obviously an extremely sensitive and critical issue, then why not require that these
particularized medicines be reasonably available to the people for and arguably
by whom they were made? It is hard to argue that six months of suffering from
a terminal illness is morally different from an emergency abortion.
Further, if people are really concerned with terminal patients' "right to try,"
then why not expand that right to affordability by limiting exclusion rights
instead of granting access to treatment that has not been properly researched?
The "right to try" laws currently on the floor of the Senate pertain to medications
that have only passed stage one of the FDA approval process.10 9 However, only
33% of medications advance from stage 2 to stage 3.110 This means that the law
gives terminal patients access to the 67% of drugs that would have been rejected,
and the patients will be vulnerable to extreme risks and potentially painful side
effects. Alternatively, by limiting the exclusion rights of the pharmaceutical
companies' control of personalized medicine, patients would not only have
better access to the pharmacogenomics, but the treatment would have a higher
chance of success than those that merely passed phase one of the development
process.
109 S. Res. 204, 115th Cong. (2017) (enacted).
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Granting the public access to pharmacogenomics would likely cause a shift
in the economic structure of pharmaceutical companies because they would not
have the exclusive rights that normally allow them to have a monopoly over new
medications. This leads some to have the fear that pharmaceutical companies
will stop producing potential life-sustaining or lifesaving treatments and
researching new ones. However, universities and research labs, not
pharmaceutical companies, are the entities doing most of the current research
for groundbreaking biologics.111 Further, pharmaceutical companies are already
looking for other sources for income other than their patent tights on drugs.
112
Knockoffs and genetics are becoming too easy to make, and these particularized
medicines do not have the same type of versatility or broad market like their big
moneymakers do.1 3 Therefore, it is likely that pharmaceutical companies will be
forced to make a market shift for maintaining their profits before particularized
medicines are on the market. And, therefore, to reduce their exclusive rights over
pharmacogenomics will not be a substantial enough deterrent to reduce their
economic incentives from producing any pharmacogenomics.
IV. CONCLUSION
What happens to innovation if companies face the possibility of having to
"donate" their new drugs to ill patients? Will a "right to try" necessarily deter
pharmaceutical companies from continuing to innovate in the field of
personalized medicine? Will states need to step in and establish a reimbursement
method that encourages innovation but also gives access to the medication that
was created specifically for the patient?
The concept of medical self-defense should be expanded beyond emergency
abortions. New right-to-try laws show a moral shift in our society that
encourages providing terminal patients with all available options. And under our
understanding of property rights, if a medication is developed using the genetic
information of individuals, then they should have a right to access that
medication, even if they would otherwise not be able to afford it.
If society wants to avoid the circumstance that would allow a pharmaceutical
company to have a monopoly over a patient's only chance at survival, it must
embrace these alternative reimbursement methods and allow patients, when it is
medically necessary, to have access to the treatments that were designed for
them.
111 Shuai Xu and Aaron S. Kesselheim, Medical Innovation Then and Now: Perspecfives of Innovators
Responsiblefor Traniformative Drugs, 42 J. OF L., MED., & ETHICS 564 (Winter 2014).
112 Id. at 572.
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